Question: ChIP-seq in cancer cell lines
gravatar for Ming Tang
5.9 years ago by
Ming Tang2.6k
Houston/MD Anderson Cancer Center
Ming Tang2.6k wrote:

I did not realize that this is a problem. If I do a ChIP-seq using a cancer cell line which harbors numerous translocations and chromosome duplications, how can I map them? Using a non-cancer human reference genome will make the peaks off coordinates. Should I create a reference genome for that cancer cell line?

Or I can still map to the reference genome, and by using whole genome DNA sequencing to identify translocations and duplications. and then move the peaks to the "right" places according to the translocation/duplication information.

Any thoughts on that?

Thank you.

chip-seq • 1.8k views
ADD COMMENTlink modified 4.8 years ago by khaynes40 • written 5.9 years ago by Ming Tang2.6k
gravatar for Devon Ryan
5.9 years ago by
Devon Ryan97k
Freiburg, Germany
Devon Ryan97k wrote:

What's the end goal? If you just want to call differential peaks (e.g., between treated and control samples) then the exact coordinates don't matter. If, however, you're interested in where the peaks are relative to some features (genes, CpG islands, etc.), then you only need to care about structural changes whose end points are extremely close to one of those features (i.e., close enough to matter in the analysis, since the coordinate change could alter the results). In that case, I'd map to the regular reference and just post-process those few sites (the fewer the sites, the easier it is to ensure you've handled them correctly!).

In general, it's probably simplest to not create a new reference unless absolutely needed.

ADD COMMENTlink written 5.9 years ago by Devon Ryan97k

Thank you for your comment Ryan. I want to identify TF binding sites that are mis-targeted to some genes ( within say 100kb) due to chromosome rearrangement. Do you know any workflow for this purpose?

ADD REPLYlink written 5.9 years ago by Ming Tang2.6k

Not off-hand, though I'd be surprised if no one has coded anything (though whether they actually posted and documented it...).

ADD REPLYlink written 5.9 years ago by Devon Ryan97k
gravatar for khaynes
4.8 years ago by
Arizona State University, USA
khaynes40 wrote:

Unfortunately, the lack of cancer-specific reference genomes is a very big problem that is going to require a coordinated effort and a lot of resources to solve. Sequencing is getting faster, but the assembly stage, from what I understand, is not so fast. It is even more difficult when the genome has a complicated arrangement.

The best you can do for now is align your ChIP-seq reads to something like hg19 and hope for the best. I have seen evidence of non-alignment in my own ChIP-seq of U2OS cells by viewing the WIG data from an input sample as a track in the integrated genome viewer (IGV). I can see some gaps and valleys, whereas theoretically the signal should be even.

ADD COMMENTlink written 4.8 years ago by khaynes40
Please log in to add an answer.


Use of this site constitutes acceptance of our User Agreement and Privacy Policy.
Powered by Biostar version 2.3.0
Traffic: 2130 users visited in the last hour